Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -40.15 | -15.24 | -10.88 | |
| Graham Fair Price | -2.33 | 28.57 | 29.25 | |
| PEG | -94.62 | 0.24 | -4.49 | |
| Price/Book | 3.64 | 2.99 | 2.89 | |
| Price/Cash Flow | -23.68 | -19.69 | -15.92 | |
| Prices/Earnings | -47.04 | -4.37 | -2.97 | |
| Price/Sales | 12.33 | 172.63 | 153.68 | |
| Price/FCF | -23.68 | -19.69 | -15.92 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.73 | 0.91 | 0.91 | |
| Operating Margin | 23.31 | -10.49 | -13.68 | |
| ROA | 25.87 | -0.14 | -0.19 | |
| ROE | -0.24 | -0.17 | 29.52 | |
| ROIC | -0.23 | -0.16 | 27.63 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.17 | -94.74 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.03 | 0.08 | 140.32 | |
| EPS QOQ | < 0.005 | 0.18 | 2631.91 | |
| FCF QOQ | 0.31 | -0.09 | -71.27 | |
| Revenue QOQ | 0.91 | 0.20 | -78.25 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 606.36 | 1270.34 | 109.50 | |
| Days Sales Outstanding (DSO) | 103.20 | 110.46 | 7.04 | |
| Inventory Turnover | 0.15 | 0.07 | -52.27 | |
| Debt/Capitalization | 0.07 | 0.05 | -22.49 | |
| Quick Ratio | 5.68 | 7.25 | 27.72 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 12.52 | 14.56 | 16.33 | |
| Cash | 13.38 | 15.02 | 12.24 | |
| Capex | -0.01 | < 0.005 | 95.53 | |
| Free Cash Flow | -2.27 | -2.21 | 2.52 | |
| Revenue | 0.24 | 0.25 | 7.33 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Best
Fundamentals
Financial Health
06 - Financial Health ·
Bad